Syngene International KMP Change: Siddharth Mittal Appointed MD & CEO from July 01, 2026

2 min read     Updated on 30 Apr 2026, 03:34 AM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Syngene International Limited has announced a leadership transition with Siddharth Mittal appointed as Managing Director & CEO effective July 01, 2026, replacing Peter Bains. The Board approved this KMP change on April 29, 2026 under Regulation 30 of SEBI Listing Regulations, with Mr. Mittal authorized to determine materiality of events and disclosures to stock exchanges.

powered bylight_fuzz_icon
39032610

*this image is generated using AI for illustrative purposes only.

Syngene International Limited has announced a significant change in its Key Managerial Personnel (KMP) structure, with the Board of Directors approving the appointment of Mr. Siddharth Mittal as the new Managing Director and Chief Executive Officer. The decision was made during a Board meeting held on April 29, 2026, pursuant to Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Leadership Transition Details

Mr. Peter Bains will step down as the Managing Director & CEO effective from the close of business hours on June 30, 2026. Consequently, Mr. Siddharth Mittal will assume the role of Managing Director & CEO effective July 01, 2026. The Board has also approved amendments to the Policy on Determination of Materiality of Events and Information to be disclosed, authorizing Mr. Siddharth Mittal to determine materiality of events or information and make necessary disclosures to the Stock Exchange(s).

Parameter Details
Board Approval Date April 29, 2026
Outgoing MD & CEO Mr. Peter Bains
Incoming MD & CEO Mr. Siddharth Mittal
Transition Effective Date July 01, 2026

Key Managerial Personnel Structure

The company has outlined the current and revised KMP structure with complete contact details. Mr. Deepak Jain continues as Chief Financial Officer and Mr. Chethan Yogesh remains Company Secretary and Compliance Officer.

Current KMP Structure (As of April 29, 2026):

Position Name Email ID Contact No.
Managing Director & CEO Mr. Peter Bains Peterbains@syngeneintl.com 080-6891-3135
Chief Financial Officer Mr. Deepak Jain deepak.jain@syngeneintl.com 080-6775-9689
Company Secretary & Compliance Officer Mr. Chethan Yogesh Chethan.Yogesh@syngeneintl.com 080-6891-8781

New KMP Structure (Effective July 01, 2026):

Position Name Email ID Contact No.
Managing Director & CEO Mr. Siddharth Mittal siddharth.mittal1@syngeneintl.com 080-6891-3135
Chief Financial Officer Mr. Deepak Jain deepak.jain@syngeneintl.com 080-6775-9689
Company Secretary & Compliance Officer Mr. Chethan Yogesh Chethan.Yogesh@syngeneintl.com 080-6891-8781

Regulatory Compliance

The announcement has been made in compliance with Regulation 30(5) of SEBI Listing Regulations, 2015. The company has confirmed that this information will be made available on its official website at www.syngeneintl.com , ensuring transparency and adherence to regulatory requirements. The communication was formally signed by Chethan Yogesh, Company Secretary and Compliance Officer, on April 29, 2026.

Historical Stock Returns for Syngene International

1 Day5 Days1 Month6 Months1 Year5 Years
+8.21%+7.27%+12.52%-29.06%-25.64%-18.75%

What strategic changes might Syngene International implement under Mr. Siddharth Mittal's leadership compared to the previous management approach?

How could this leadership transition impact Syngene's competitive position in the contract research and manufacturing services sector?

Will the new CEO's appointment lead to any shifts in Syngene's geographic expansion plans or client acquisition strategy?

like17
dislike

Biocon Limited Declares No Share Encumbrance by Promoters for FY 2025-26

1 min read     Updated on 24 Apr 2026, 06:48 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Biocon Limited declared no share encumbrance by promoters and promoter group entities for FY 2025-26, submitting the formal declaration on April 02, 2026. The company confirmed compliance with SEBI Regulation 31(4) regarding substantial acquisition of shares and takeovers, with Company Secretary Rajesh Umakant Shanoy signing the declaration covering the period ending March 31, 2026.

powered bylight_fuzz_icon
38539090

*this image is generated using AI for illustrative purposes only.

Biocon Limited has formally declared that its promoters and promoter group entities maintained no encumbrance on shares throughout the financial year 2025-26. The biotechnology company submitted this declaration on April 02, 2026, in compliance with regulatory requirements under SEBI's takeover regulations.

Regulatory Compliance Declaration

The declaration was made pursuant to Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Syngene International received formal notification along with both major stock exchanges regarding this compliance matter.

Parameter: Details
Declaration Date: April 02, 2026
Financial Year Covered: 2025-26
Year-end Date: March 31, 2026
Signatory: Rajesh Umakant Shanoy
Designation: Company Secretary and Compliance Officer

Share Encumbrance Status

The company confirmed that none of the entities belonging to the promoter and promoter group category, along with persons acting in concert, created any encumbrance on shares held directly or indirectly in the company. This declaration covers the entire duration of the financial year 2025-26 and the position as of March 31, 2026.

Corporate Communication

Company Secretary and Compliance Officer Rajesh Umakant Shanoy, membership number ACS 16328, digitally signed the declaration from Bengaluru. The formal communication was addressed to multiple parties including the Audit Committee Chairperson, BSE Limited's Department of Corporate Services, and the National Stock Exchange of India Limited's Corporate Communication Department.

This declaration represents standard regulatory compliance for listed companies, ensuring transparency in promoter shareholding patterns and maintaining investor confidence through proper disclosure of any potential encumbrances on promoter holdings.

Historical Stock Returns for Syngene International

1 Day5 Days1 Month6 Months1 Year5 Years
+8.21%+7.27%+12.52%-29.06%-25.64%-18.75%

Will Biocon's promoters consider pledging shares for future expansion financing or strategic acquisitions?

How might this clean shareholding structure position Biocon for potential partnerships with global pharmaceutical companies?

Could Biocon's unencumbered promoter holdings make it a more attractive target for institutional investors or merger activities?

like15
dislike

More News on Syngene International

1 Year Returns:-25.64%